Corrections Noted in Table 2 of the Melanoma Self Surveillance Trial Article

Overview

This report addresses corrections made to Table 2 in the Melanoma Self Surveillance Trial article, specifically regarding the perceived chance of developing new melanoma. The corrections are crucial for accurate interpretation of risk perception data among participants.

Background

Accurate data reporting is essential in clinical trials, particularly in studies related to melanoma where patient self-surveillance is becoming increasingly important. The Melanoma Self Surveillance Trial aims to enhance early detection strategies, which are vital given the rising incidence of melanoma. Understanding participants' perceptions of risk can influence their engagement in self-surveillance practices.

Data Highlights

Corrections made to Table 2 regarding the perceived chance of developing a new melanoma were necessary due to switched percentages. Additionally, two figures were missing from Supplement 3 of the original article.

Key Findings

• Errors in Table 2 of the Melanoma Self Surveillance Trial were corrected online.
• Participants' perceived risk of melanoma is critical for understanding their engagement in self-surveillance.
• Fear of recurrence among participants was linked to their perceived risk of developing melanoma.
• Patient-led surveillance models are gaining traction in melanoma follow-up care.
• Accurate reporting of risk perception variables is essential for interpreting trial outcomes.

Clinical Implications

Clinicians should ensure accurate communication of risk perception data to enhance patient engagement in self-surveillance. The corrections made in the trial highlight the importance of data integrity in clinical research, which can directly impact patient outcomes.

Conclusion

The corrections to the Melanoma Self Surveillance Trial underscore the importance of precise data reporting in clinical studies. Accurate risk perception is vital for effective patient self-surveillance and early detection of melanoma.

Related Resources & Content

1. The ASCO Post, August 15, 2013 -- 'Alarming Difference' in Survival Outcomes for Young White Men with Melanoma
2. The ASCO Post, July 25, 2015 -- Capitalizing on Increased Interest in Skin Cancer During Summer to Reeducate People About Sunscreens and ‘Smart Sun Strategies’
3. Journal of Neuro-Oncology, 2025 -- Amendment to: PIK3R2 Immunostaining as a Prognostic Indicator in Newly Diagnosed Glioblastoma Patients Undergoing Autologous Tumor Vaccine Treatment
4. ESMO Diagnosis, Treatment and Follow-up of Cutaneous Melanoma Guideline Summary - Guideline Central
5. Characteristics of Participants Screened and Randomized to the Melanoma Self Surveillance Trial | JAMA Dermatology | JAMA Network
6. Journal of Neuro-Oncology — Erratum: Enhanced Disease-Free Survival in Leptomeningeal Metastasis for EGFR-Mutated Non-Small Cell Lung Cancer Patients via Local Cranial Radiation and Third-Generation Tyrosine Kinase Inhibitors
7. ESMO Diagnosis, Treatment and Follow-up of Cutaneous Melanoma Guideline Summary - Guideline Central
8. Characteristics of Participants Screened and Randomized to the Melanoma Self Surveillance Trial | JAMA Dermatology | JAMA Network
9. Teledermatology and Teledermoscopy for Melanoma Care Pathways: Timeliness, Diagnostic Performance, and Stage at Diagnosis: A Systematic Review | MDPI